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as well as of Ly6chi macrophages, for up to 7 days follow-
ing a single administration. MDSC depletion was dose 
dependent and more effective with MC-TG than with equal 
doses of free TG. Finally, we tested whether this MDSC-
depleting strategy might enhance cancer immunotherapies 
in the B16-F10 melanoma model. We found that MC-TG 
significantly improved the efficacy of adoptively trans-
ferred, OVA-specific CD8+ T cells in melanoma cells 
expressing OVA. These findings highlight the capacity of 
MC-TG in depleting MDSCs in the tumor microenviron-
ment and show promise in promoting anti-tumor immunity 
when used in combination with T cell immunotherapies.
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Abstract Myeloid-derived suppressor cells (MDSCs) are 
a heterogeneous population of immature myeloid cells that 
suppress effector T cell responses and can reduce the effi-
cacy of cancer immunotherapies. We previously showed 
that ultra-small polymer nanoparticles efficiently drain 
to the lymphatics after intradermal injection and target 
antigen-presenting cells, including Ly6chi Ly6g− mono-
cytic MDSCs (Mo-MDSCs), in skin-draining lymph nodes 
(LNs) and spleen. Here, we developed ultra-small polymer 
micelles loaded with 6-thioguanine (MC-TG), a cytotoxic 
drug used in the treatment of myelogenous leukemia, with 
the aim of killing Mo-MDSCs in tumor-bearing mice and 
thus enhancing T cell-mediated anti-tumor responses. We 
found that 2 days post-injection in tumor-bearing mice 
(B16-F10 melanoma or E.G7-OVA thymoma), MC-TG 
depleted Mo-MDSCs in the spleen, Ly6clo Ly6g+ granulo-
cytic MDSCs (G-MDSCs) in the draining LNs, and Gr1int 
Mo-MDSCs in the tumor. In both tumor models, MC-TG 
decreased the numbers of circulating Mo- and G-MDSCs, 
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LN  Lymph node
MC  Micelle
MDSC  Myeloid-derived suppressor cell




PEG  Poly(ethylene glycol)
PPS  Poly(propylene sulfide)
p.i.  Post-tumor inoculation
RA  Retinoic acid
RBC  Red blood cell
TG  6-Thioguanine
Introduction
Over the past decades, many novel cancer immunothera-
pies have been developed to boost anti-tumor immunity, 
targeting a variety of mechanisms including tumor anti-
gen presentation by dendritic cells (DCs), anti-tumor T 
cell priming, overall T cell activation status, immune sup-
pression, and T cell infiltration in the tumor [1, 2]. Strat-
egies have included cell-based therapies such as transfer 
of ex vivo activated DCs or engineered T cells as well as 
antibody-based therapies that target specific T cell inhibi-
tory pathways including CTLA-4 or PD-1/PD-L1 [3–6]. 
Despite these efforts, many therapeutic modalities encoun-
ter limited success because of tumor-induced immune sup-
pression and evasion mechanisms [6–9]. It has been shown 
that targeting these immune suppressive mechanisms 
can lead to enhanced immunotherapy efficacy in cancer 
[10–14].
Myeloid-derived suppressor cells (MDSCs) are a het-
erogeneous population of immature myeloid cells, charac-
terized by their expression of CD11b and Gr1 and lack of 
MHCII; they comprise a Ly6chi Ly6g− Gr1int monocytic 
subset (Mo-MDSCs) and a Ly6clo Ly6g+ Gr1hi granulo-
cytic subset (G-MDSCs) [15]. MDSCs are induced by 
tumor-mediated inflammation [16–18], recruited to the 
circulation via tumor-derived factors such as IL-1, IL-6, 
GM-CSF, G-CSF, and VEGF [19–21], and accumulate in 
the tumor, tumor-draining lymph node (LN), and spleen, 
with MDSC numbers increasing with tumor load [16, 21]. 
MDSCs play a major role in anti-tumor immunity by inhib-
iting both CD8+ and CD4+ T cell activation, proliferation, 
and homing [16, 17, 22, 23]. G-MDSCs infiltrate and exert 
their suppressive activity in an antigen-specific manner in 
the LNs, while Mo-MDSCs, considered as the more sup-
pressive ones, infiltrate and suppress T cell responses in the 
spleen and tumor [18, 24–26].
Strategies to target MDSCs, and thereby improve local T 
cell function, include depletion (affecting both recruitment 
and expansion in the tumor), functional inhibition, and dif-
ferentiation into mature antigen-presenting cells [27, 28]. 
Ly6chi monocytes and Mo-MDSCs traffic from the bone 
marrow (BM) to sites of inflammation via CCR2-signaling 
[29], and therapeutic strategies based on CCR2-siRNA 
showed significant reduction in inflammatory monocyte 
effects in murine models of atherosclerosis, cancer, and 
diabetes [30]. Also, all-trans-retinoic acid (RA), which is 
important for hematopoietic stem cell development [31], 
was shown to eliminate immature myeloid cells in tumor-
bearing mice and drive their differentiation into mature 
myeloid cells in cancer patients [10, 32, 33], although 
without affecting tumor growth. The chemotherapeutic 
pyrimidine analogs gemcitabine and 5-fluorouracil, which 
prevent DNA replication and lead to apoptosis, have shown 
efficacy in depleting MDSCs in tumors and lymphoid 
organs, leading to expansion of tumor-specific T cells and 
delayed tumor growth in mice [34, 35]. High doses of the 
TLR9 agonist CpG have been shown to impact both Ly6g+ 
and Ly6chi MDSCs in tumor-bearing mice by decreasing 
their suppressive function and leading to their differentia-
tion into mature myeloid cells [36, 37]. Finally, combining 
adoptive T cell therapy or DC transfer with cytotoxic drugs 
or small molecule inhibitors has shown some promise in 
slowing tumor growth [38–41].
The purine analog 6-thioguanine (TG) is an effective 
anti-inflammatory and anticancer drug [42]. It is used in 
pediatric and adult leukemias, including myeloid and mye-
logenous leukemias [43, 44], where it can “freeze” myelo-
blasts in an immature state to prevent their differentiation 
into mature myeloid cells, including monocytes and gran-
ulocytes [18, 45]. We hypothesized that TG might be an 
interesting drug candidate to deplete Mo-MDSCs based on 
its ability to target the myeloid cell lineage.
MDSC-directed strategies have been shown to enhance 
anti-tumor immunity and to synergize with anticancer vac-
cines [10, 11, 40]. Our laboratory has developed nano-
particles (NPs) that drain from i.d. administration sites 
through lymphatics to target skin-draining LNs, where they 
are taken up by resident antigen-presenting cells [46, 47]. 
In a biodistribution study, we showed that NPs are taken 
up remarkably effectively by Mo-MDSCs in LNs, spleen, 
and tumor [47]. Based on this observation, we developed a 
nanoscale polymeric micelle (MC) capable of sequestering 
and releasing TG, with the intention of depleting MDSCs 
in a more targeted manner than might be achievable with 
free TG. MCs consist of TG chemically conjugated via 
a disulfide bond to a block copolymer of the hydrophilic 
polyethylene glycol (PEG) and the hydrophobic polypro-
pylene sulfide (PPS) [48]. After first finding that MC-TG 
entirely depleted BM-derived Mo-MDSCs, we then tested 
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the effect of MC-TG on MDSCs in two different tumor 
models in mice and assessed the efficacy of the drug in 
micellar compared to soluble form. Finally, we combined 
our MDSC-targeting strategy with two modes of cancer 
immunotherapy and demonstrated that MC-TG enhances 
the efficacy of adoptive T cell immunotherapy.
Materials and methods
Mice and cell lines
C57BL/6 female mice, aged 8–12 weeks, were obtained 
from Harlan (France) and OT-I mice, C57BL/6-
Tg(TcraTcrb)1100Mjb/J, from Charles River Laboratories 
(France). All experiments were performed with approval 
from the Veterinary Authority of the Canton de Vaud (Swit-
zerland) according to Swiss Law.
E.G7-OVA thymoma cells (OVA-expressing EL-4 cells, 
ATCC CRL-2113) and B16-F10 melanoma cells (ATCC 
CRL-6475) were obtained from American Type Culture 
Collection (Manassas, VA, USA). Ovalbumin-expressing 
B16-F10 cells (B16.OVA) were a kind gift of Bertrand 
Huard (University Medical Center, Geneva, Switzerland). 
E.G7-OVA cells were cultured in RPMI 1640 medium sup-
plemented with 10 % FBS, 10 mM HEPES, 1 mM sodium 
pyruvate (all from Life Technologies, Carlsbad, CA, USA), 
0.05 mM β-mercaptoethanol, and 0.4 mg/ml G418 (Brun-
schwig, Basel, Switzerland); they were expanded in G418-
free media just before inoculation. B16-F10 cells were 
maintained in DMEM supplemented with 10 % FBS.
Reagents
Chemicals, including 6-thioguanine, were reagent 
grade and purchased from Sigma-Aldrich (Saint Louis, 
MO, USA). 5′ SPO3-CpG oligonucleotide (5′-TCCAT-
GACGTTCCTGACGTT-3′) was purchased from 
Microsynth (Balgach, Switzerland). Low-endotoxin-grade 
OVA (<0.01 EU/μg protein), used for immunization, was 
from Hyglos (Bernried, Germany), and OVA grade VI, 
used for restimulation, was purchased from Sigma-Aldrich. 
IL-6 and GM-CSF were purchased from Peprotech (Oak 
Park, CA, USA).
Nanoparticle synthesis and formulation
NP‑OVA and NP‑CpG
Pluronic-stabilized PPS NPs were synthesized by emul-
sion polymerization and surface functionalized as previ-
ously described [49]. Before and after conjugation, the size 
of NPs was determined by dynamic light scattering (DLS) 
(Zetasizer, Nano ZS, Malvern Instruments, Malvern, UK) 
and was approximately 30 nm. OVA and CpG were conju-
gated to NPs as previously described [50]. Concentrations 
of OVA and CpG on NPs were determined by Pierce BCA 
protein assay (Perbio Thermo Fischer Scientific, Waltham, 
MA, USA) and by GelRed assay (Brunschwig, Basel, 
Switzerland), respectively. All NP formulations displayed 
endotoxin levels lower than 0.1 EU per dose administered 
to mice, as detected using the HEK-Blue hTLR4 cells from 
Invivogen (San Diego, CA, USA).
MC‑TG
MC-TG was formed as previously described [48]. Briefly, 
PEG–PPS–SS–TG was dissolved by vortexing and gen-
tle heating in N-methyl-2-pyrrolidone to 100 mg/ml. The 
pale yellow solution was added dropwise to stirred endo-
toxin-free water at a 1:9 volume ratio (polymer/water) and 
stirred for 10 min. The mixture was then transferred to a 
3500 MWCO cellulose membrane (Spectrum Laborato-
ries, Rancho Dominguez, CA, USA) and dialyzed against 
water overnight. Formed MCs were then collected, filtered 
(0.22 μm), and concentrated in 3000 MWCO Amicon filter 
tubes according to manufacturer’s instructions (Millipore, 
Billerica, MA, USA). The concentration of TG was meas-
ured by UV/Vis at 340 nm by first releasing TG by TCEP 
reduction. Formed MCs (MC-TG) had a concentration of 
10–12 μM TG and a diameter of 25 nm by DLS (supple-
mentary Fig. S1).
In vitro assays of MDSCs
Culture of BM‑derived MDSCs
BM-derived MDSCs were cultured as reported [51]. 
BM from C57BL/6 femurs and tibias were collected in 
RPMI 1640 medium supplemented with 10 % FBS, 1 % 
penicillin/streptomycin, 10 mM HEPES, and 20 μM 
β-mercaptoethanol (MDSC media). Cells were filtered 
through a 70-μm strainer, and red blood cells (RBCs) were 
lysed 5 min at room temperature with NH4Cl. Cells were 
plated at a density of 164,000 cells/ml in 12-well plates or 
at 250,000 cells/ml in petri dishes with 40 ng/ml IL-6 and 
40 ng/ml GM-CSF. Cells were incubated 4 days and then 
collected for analysis or replated and incubated for another 
3 days.
OVA‑specific CD8+ T cell proliferation assay
2 × 105 OT-I splenocytes were plated in 96-well plates and 
co-cultured with BM-derived MDSCs at varying concen-
trations (2 × 105 MDSCs correspond to 100 % MDSCs to 
splenocytes, and no MDSCs correspond to 0 % MDSCs to 
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splenocytes). Cells were cultured in MDSC medium and 
incubated 24 h with 250 μg/ml OVA grade VI. 0.5 μCi of 
3H thymidine was added to each well, and cells were fur-
ther incubated for 18 h. Cells were then stored at −20 °C 
before collection on filter plates and analysis by a scintilla-
tion counter to determine thymidine incorporation.
Tumor inoculation and injections
Mice were anesthetized with isoflurane (5 % for induction 
and 2 % for maintenance) and injected with 106 E.G7-OVA 
cells, 5 × 105 B16-F10 cells, or 2.5 × 105 B16.OVA cells 
in 30 μl 0.9 % saline solution intradermally (i.d.) on the left 
side of the back. E.G7-OVA, B16-F10, or B16.OVA tumor-
bearing mice were injected 7, 5, or 4 days post-tumor 
inoculation (p.i.), respectively, with 10 mg/kg MC-TG or 
free TG injected i.d. in all four footpads (unless otherwise 
specified) in the following experiments:
Biodistribution MC-TG was labeled with the fluoro-
phore Dy649; mice were killed on day 9;
Time course blood was sampled every 2–3 days starting 
on injection day;
Multiple doses mice were boosted on day 13 with 5 mg/
kg MC-TG;
Dosage mice were injected with 2, 5, or 10 mg/kg 
MC-TG on day 7 and killed on day 14;
NP-vaccine mice were immunized on days 3 and 10 
with 10 μg NP-OVA and 1 μg NP-CpG (NP-vaccine) 
i.d. in the front footpad draining the tumor; mice were 
injected with 10 mg/kg MC-TG on day 13;
Adoptive T cell transfer 10 mg/kg MC-TG or free TG was 
injected i.d. on day 4 p.i., and 2 days later (day 6 p.i.), 106 
OT-I CD8+ T cells were transferred i.v. in the tail vein.
Blood was sampled from the submandibular vein of the 
cheek with a 4-mm lancet at indicated time points. Tumors 
were measured starting 5 days p.i. with a digital caliper, 
and volumes (V) were calculated as an ellipsoid (V = π/6 · l 
·w · h, where l is length, w width, and h height). Mice were 
killed by CO2 asphyxiation. Experiments were stopped 
when tumor volumes reached 1 cm3 or earlier if necrotic.
Adoptive CD8+ T cell transfer
Splenic CD8+ T cells from OT-I mice cells were isolated by 
immunomagnetic negative selection (EasySep Mouse CD8+ T 
Cell Isolation Kit) and CD11c+ by positive selection (EasySep 
Mouse CD11c Positive Selection Kit), both from Stemcell 
Technologies (Vancouver, BC, Canada). CD8+ and CD11c+ 
cells were co-cultured 72 h at a ratio of 10:1 with 1 nM OVA257-
264 peptide (Genscript, Piscataway, NJ, USA) and 10 U/ml 
recombinant mouse IL-2 (Roche, Rotkreuz, Switzerland). Cells 
were then collected, washed in basal medium, and resuspended 
to 107 cells/ml prior to tail vein injection.
Tissue and cell preparation
Spleens, LNs (brachial, axillary, inguinal), and tumors were 
harvested at time of killing. LNs and tumors were digested 
20 and 60 min, respectively, in DMEM supplemented with 
1 mg/ml collagenase D (Roche). Single-cell suspensions 
were obtained by gently disrupting the organs through a 
70-μm cell strainer. Spleen and blood RBCs were lysed 
with NH4Cl 5 min. Cells were counted and resuspended in 
IMDM supplemented with 10 % FBS and 1 % penicillin/
streptomycin (full medium) (all from Life Technologies).
Flow cytometry
Cells were washed and stained with surface antibodies in 
staining buffer [HBSS (Life Technologies) supplemented 
with 0.5 % bovine serum albumin]. Cell viability was deter-
mined by propidium iodide incorporation in staining buffer 
after surface antibody staining or with live/dead fixable cell 
viability reagent (Life Technologies) in PBS before anti-
body staining. Cells were stained with PE-labeled H-2Kb/
OVA257–264 pentamer (Proimmune, Oxford, UK) according 
to manufacturer’s instructions.
AccuCount cell counting beads (Spherotech, Lake For-
est, IL, USA) were added to blood samples. Samples were 
acquired on CyAn ADP analyzer (Beckman Coulter, Brea, 
CA, USA), and data were analyzed with FlowJo software 
(v9.4; Tree Star, Ashland, OR, USA). Antibodies against 
mouse CD8, CD3, MHCII, B220, CD45, CD11b, Gr1, 
Ly6c, Ly6g, and CD11c were purchased from eBioscience 
or BioLegend (San Diego, CA, USA). Pacific orange-con-
jugated and Alexa Fluor 647-conjugated streptavidins were 
from Life Technologies.
Statistical analysis
Statistically significant differences between experimental 
groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni posttest correction with 
Prism software (v5, GraphPad, San Diego, CA, USA). 
*, **, and *** indicate P values <0.05, 0.01, and 0.001, 
respectively.
Results
MC‑TG depletes BM‑derived Mo‑MDSCs in vitro
Based on the hypothesis that TG in a nanoparticulate for-
mulation may be more readily targeted to MDSCs than in 
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soluble form [47], we formulated TG as a 25-nm micelle 
(MC-TG) by linking TG to a PEG–PPS chain via a 
disulfide bond (supplementary Fig. S1) [48]. We generated 
MDSCs in vitro following a well-established protocol [51] 
(supplementary Fig. S2 A) using IL-6 and GM-CSF, two 
factors secreted by tumors that recruit MDSCs from the 
BM to the circulation in tumor-bearing mice [19–21]. After 
4 days of culture, BM cells were skewed toward a CD11b+ 
MHCII− CD11c− immature myeloid phenotype character-
istic of MDSCs, with Ly6chi Ly6g− Mo-MDSC and Ly6clo 
Ly6g+ G-MDSC subsets (supplementary Fig. S2 B) [16].
TG, in both free and micellar forms, depleted Mo-
MDSCs in vitro (Fig. 1a). Mo-MDSCs were reduced from 
5.6 ± 0.5 % of the culture to 0.1 % (**) of the culture with 
free TG and MC-TG. While control MDSCs efficiently 
prevented OT-I T cell proliferation, adding either free TG 
or MC-TG to MDSCs rendered them less suppressive 
(Fig. 1b). Furthermore, both MC-TG and free TG depleted 
already differentiated Mo-MDSCs by day 7 in vitro 
(Fig. 1c), from 3.9 ± 0.7 to 0.2 and 0.3 %, respectively, and 
rendered BM-derived MDSCs less suppressive than control 
MDSCs (Fig. 1d). While a ratio of approximately 1:8 of 
control MDSCs/splenocytes (12 %) was needed to achieve 
a 50 % reduction in T cell proliferation, approximately 
40 % TG-treated MDSCs were needed to achieve equiva-
lent inhibition of T cell proliferation (Fig. 1d). These results 
show that TG, in both free and micellar forms, can deplete 
BM-derived Mo-MDSCs in vitro and can render MDSCs 
overall less suppressive against T cell proliferation.
MC‑TG targets and depletes MDSCs in the spleen, 
LNs, and tumor after 2 days
Next, we investigated the effects of MC-TG on MDSCs 
in vivo. E.G7-OVA tumor-bearing mice were injected 
with fluorescently labeled MC-TG (for tracking purposes) 
7 days p.i. (Fig. 2a). MC-TG did not affect frequencies 
of CD45+ cells (Fig. 2b) and was efficiently taken up by 
both Mo-MDSCs and G-MDSCs in the spleen and LNs 
of tumor-bearing mice 2 days post-injection (Fig. 2c, d 
upper). Spleen DCs and macrophages (Mϕ), but not B or T 
cells, also took up MC-TG (Fig. 2c, d middle). After 2 days, 
MC-TG selectively decreased frequencies of Mo-MDSCs 
in the spleen and G-MDSCs in LNs, leaving other tar-
geted cells unaffected at this time point (Fig. 2c, d lower). 
All tumor MDSC subsets took up MC-TG (Fig. 2e upper), 
and MC-TG also associated with tumor-associated DCs, 
Mϕ, and B cells (Fig. 2e middle). MC-TG significantly 














































































Fig. 1  MC-TG depletes BM-derived Mo-MDSCs in vitro. a, b BM 
cells were incubated for 4 days in media conditioned with 1 μM free 
TG or MC-TG, after which cells were analyzed by flow cytometry 
or co-cultured with OT-I splenocytes and OVA: a representative flow 
cytometry plots of CD11b+ MHCII− CD11c− immature myeloid 
cells stained for Ly6c and Ly6g (values in the dot plots represent per-
centage of CD11b+ MHCII− CD11c− cells in each gate) (average 
values are given in the text); b OT-I T cell proliferation as determined 
by 3H thymidine incorporation. c, d BM cells were incubated for 
4 days to allow MDSC differentiation, after which they were replated 
in medium conditioned with 1 μM free TG or MC-TG and incubated 
for 3 days: c representative flow cytometry plots of immature mye-
loid cells stained for Ly6c and Ly6g (values in the dot plots represent 
percentages of CD11b+ MHCII− CD11c− cells in each gate; average 
values are given in the text); d OT-I T cell proliferation as determined 
by 3H thymidine incorporation
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decreased the frequency of tumor-infiltrating Gr1int Mo-
MDSCs and increased Gr1hi G-MDSCs, but did not affect 
other targeted cells (Fig. 2e lower). Taken together, these 
results show that MC-TG acts on Mo-MDSCs in the spleen, 
G-MDSCs in the LNs, and Gr1int Mo-MDSCs in the tumor. 
MC-TG and TG seemed well tolerated.
MC‑TG depletes circulating Mo‑MDSCs 
and G‑MDSCs in tumor‑bearing mice
Next, we sought to characterize the temporal effects of 
free TG and MC-TG. While one dose of free or MC-TG 
did not impact E.G7-OVA tumor growth (Fig. 3a), MC-TG 
significantly reduced frequencies of Mo-MDSCs and 
G-MDSCs in the blood, with almost no Mo-MDSCs 
and G-MDSCs remaining 7 days post-MC-TG injec-
tion (Fig. 3b, c), which also corresponded to a reduc-
tion in total leukocytes on day 14 (Fig. 3d). Free TG also 
decreased Mo-MDSCs, but did not entirely deplete them 
as did MC-TG. Free TG or vehicle control did not affect 
G-MDSC frequencies (Fig. 3c). Interestingly, both MDSC 
subsets repopulated the blood compartment on day 16 and 
even surpassed steady-state values by day 18 p.i.. CD11b+ 
MHCII+ Mϕ were left unaffected by TG except on day 14 
(Fig. 3e), when both Ly6chi CD11b+ MHCII+ Mϕ (mono-








































































































































































































































































Fig. 2  MC-TG targets and depletes MDSCs in the spleen, LNs, 
and tumor after 2 days. a Injection timeline of E.G7-OVA tumor-
bearing mice injected 7 days p.i. with 10 mg/kg of fluorescently 
labeled MC-TG (with Dy649) i.d. in the four footpads. Mice were 
killed 2 days later: Spleen, tumor, and LNs (axillary, brachial, ingui-
nal) were collected and analyzed by flow cytometry. b Frequency of 
CD45+ leukocytes in spleen, LNs, and tumor (as  % of live cells). c 
Spleen, d LNs, e tumor: upper representative flow cytometry plots 
of MDSCs: Ly6c (spleen, LNs) or Gr1 (tumor) staining versus fluo-
rescence of Dy649 (values in the dot plots represent percentage of 
CD45+ cells in each gate); middle mean fluorescence intensity (MFI) 
in Dy649 channel of Mo-MDSCs, G-MDSCs, DCs, Mϕ, B cells, T 
cells; lower proportion of Mo-MDSCs, G-MDSCs, DCs, Mϕ, B 
cells, T cells as percentage of CD45+ cells. Four mice per group, 
***P < 0.001, **P < 0.01, *P < 0.05. [MDSCs defined as CD11b+ 
MHCII− CD11c−, DCs as CD11c+ MHCII+, Mϕ as CD11b+ 
MHCII+, B cells as B220+, T cells as CD3+]
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substantially reduced and Ly6clo/− Ly6g− Mϕ were left 
unaffected (supplementary Fig. S3 A-C). MC-TG and solu-
ble TG had no impact on frequencies of circulating B and T 
cells (Fig. 3e).
The above experiment was reproduced in the B16-F10 
melanoma model, which is an orthotopic, more immu-
nosuppressive, and more aggressive cancer model [52]. 
As in the E.G7-OVA model, MC-TG did not affect B16-
F10 tumor growth (Fig. 3f) and depleted circulating Mo-
MDSCs 5 days post-injection (Fig. 3g left); free TG also 
reduced Mo-MDSCs but did not deplete them. G-MDSCs 
levels, not affected by free TG, were significantly 
reduced by MC-TG (Fig. 3g right). Mϕ, B, and T cells 
were not affected by MC-TG (Fig. 3h). Together, these 
results show that a single injection of MC-TG depleted 
Mo-MDSCs and G-MDSCs for 7 days in both E.G7-OVA 
and B16-F10 cancer models. MC-TG also depleted cir-
culating monocytic Ly6chi Mϕ (CD11b+ MHCII+ mature 
myeloid cells). Finally, MC-TG was more effective than 
free TG in depleting MDSCs without affecting tumor 
growth.
Dose and schedule of MC‑TG delivery modulate MDSC 
depletion
Since circulating MDSCs were restored 1 week post-TG 
injection, we sought to extend the MDSC-free window 
through multiple injections, namely on days 7 and 13 with 
10 and 5 mg/kg MC-TG or free TG, respectively (Fig. 4a), 
doses that are cumulatively under the toxic threshold [43]. 
In both free and MC-TG-treated mice, Mo-MDSCs and 
G-MDSCs were reduced for approximately 10 days before 
starting to repopulate the blood by day 20 p.i. (Fig. 4b). 
As in Fig. 3, Mϕ, B cells, and T cells were not affected by 
MC-TG or TG, as were total numbers of circulating CD45+ 
leukocytes (Fig. 4b, c).
Given the efficacy of the doses used above, we asked 
whether lower doses of MC-TG could provide similar effi-
cacy. E.G7-OVA-bearing mice were injected with MC-TG 
7 days p.i. with 2, 5, or 10 mg/kg (Fig. 5a). After 14 days, 
MC-TG-treated mice showed significantly reduced fre-
quencies of Mo-MDSCs in the blood, spleen, and tumor, 
but not in LNs (Fig. 5b). In contrast, MC-TG led to a sig-
nificant reduction in G-MDSCs levels in blood, spleen, and 
LNs, but not in the tumor (Fig. 5c). We observed a dose 
response to MC-TG, with the 10 mg/kg dose leading to a 
stronger reduction in MDSCs than the 5 mg/kg dose, which 
itself was more potent than the 2 mg/kg dose. These results 
show that two doses of MC-TG prolong MDSC depletion 
in the blood, that lower doses of MC-TG were effective 
at reducing MDSCs systemically and locally, and that the 
magnitude of MDSC depletion was dose dependent, with 
10 mg/kg being the most effective dose.
Depleting MDSCs with MC‑TG enhances the efficacy 
of adoptive T cell therapy
We next asked whether MDSC depletion with MC-TG 
could improve the efficacy of a model cancer vaccine com-
posed of OVA-conjugated and CpG-conjugated NPs [50]. 
E.G7-OVA-bearing mice were immunized 3 and 10 days 
p.i. with NP-OVA + NP-CpG and treated with 10 mg/kg 
MC-TG 13 days p.i. (supplementary Fig. S4 A). We chose 
this TG dose for its ability to deplete MDSCs systemi-
cally. After regressing, none of the tumors recurred in the 
mice receiving MC-TG, while 25 % of tumors recurred in 
immunized mice that did not receive MC-TG (supplemen-
tary Fig. S4 B). Five days post-MC-TG treatment, mice had 
almost a threefold reduction in OVA-specific CD8+ T cells 
compared to mice that did not receive MC-TG (supplemen-
tary Fig. S4 C). Immunized mice had reduced Mo-MDSC 
frequencies compared to control mice, and the addition of 
MC-TG rendered their levels undetectable by day 5 post-
treatment (supplementary Fig. S4 D). MC-TG also reduced 
the frequencies of circulating G-MDSCs and Mϕ compared 
to vaccine-only mice (supplementary Fig. S4 D).
Because MDSC depletion with MC-TG did not enhance 
anti-tumoral adaptive immunity to a vaccine targeted to 
tumor-draining LNs, we sought to assess potential benefits 
of depleting MDSCs in adoptive T cell therapy. Four days 
p.i., B16.OVA-bearing mice were injected with 10 mg/
kg MC-TG, followed by adoptive T cell therapy on day 6 
(Fig. 6a). B16.OVA tumors regressed 4 days after adoptive 
transfer (Fig. 6b). While MC-TG had no effect on B16.OVA 
tumor growth, a single dose of MC-TG prolonged tumor 
regression and delayed tumor growth in response to OT-I 
adoptive transfer, leading to significantly smaller tumors by 
day 22 p.i. (Fig. 6b). As a consequence, MC-TG + OT-I-
treated mice demonstrated significantly enhanced survival 
compared to OT-I-treated mice without MDSC depletion 
(Fig. 6c). Free TG, on the other hand, did not affect tumor 
regression beyond the effect of OT-I transfer and did not 
enhance survival of tumor-bearing mice (supplementary 
Fig. S5 A–B). As in Fig. 3, MC-TG transiently reduced 
proportions of circulating Mo-MDSCs and G-MDSCs, as 
well as of Mϕ and DCs, and all cell subsets repopulated the 
blood compartment 2 weeks post-MC-TG administration 
(day 19 p.i.) (Fig. 6d); free TG did not significantly reduce 
Mo- and G-MDSC levels (supplementary Fig. S5 C-D). B 
cells were not affected by MC-TG treatment, and propor-
tions of T cells were higher in mice that received MC-TG 
compared to other groups (Fig. 6d). Consistent with this 
observation, frequencies of endogenous CD8+ T cells 
were more elevated in groups receiving MC-TG 10 days 
p.i., and no difference was observed between OT-I trans-
ferred mice 19 days p.i. (Fig. 6e). No differences in endog-
enous (non-OT-I) CD8+ T cell phenotype were detected 
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(Fig. 6f upper). Among adoptively transferred mice, more 
OT-I CD8+ T cells had an effector (memory) and fewer a 
naïve phenotype in mice treated with MC-TG after 2 weeks 
(Fig. 6f lower). Together, these results show that MDSC 
depletion with MC-TG enhanced the anti-tumor efficacy of 
adoptively transferred OT-I CD8+ T cells, suggesting that 
MC-TG created a therapeutic period for transferred T cells 
to kill tumor cells by reducing the suppressive MDSCs in 
the tumor microenvironment. These results also confirm the 
therapeutic superiority of MC-TG over free TG in the con-
text of adoptive T cell immunotherapy.
Discussion
In this study, we explored the use of MC-TG as MDSC-tar-
geting and MDSC-depleting agent in tumor-bearing mice. 
We found that MC-TG effectively depleted Mo-MDSCs in 
vitro and in vivo in two different tumor models. In tumor-
bearing mice, MC-TG also targeted G-MDSCs and Ly6chi 
MΦ. Although targeting MDSCs with MC-TG did not 
enhance the efficacy of a model cancer vaccine, it enhanced 
therapeutic benefits of adoptive T cell therapy, suggesting 
that using MC-TG for efficiently depleting MDSCs may 
improve the efficacy of adoptively transferred anti-tumor T 
cell therapies.
We first demonstrated the efficacy of MC-TG in deplet-
ing BM-derived Mo-MDSCs (Fig. 1). This in vitro model 
has limitations in that cells are derived from naïve mice 
rather than from tumor-bearing mice. When the drug had 
good access to cells in vitro, obviating the need for targeted 
delivery, free TG was as effective as the micellar form, 
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Fig. 4  Two doses of MC-TG deplete circulating MDSCs over 
2 weeks. a Injection timeline of E.G7-OVA tumor-bearing mice 
injected 7 days p.i. with 10 mg/kg MC-TG i.d. in the four foot-
pads and boosted on day 13 with 5 mg/kg MC-TG. b Proportion of 
Mo-MDSCs, G-MDSCs, Mϕ, B cells, and T cells as percentage of 
CD45+ cells. c Number of CD45+ leukocytes per 100 μl of blood. 
Experiment repeated, five mice per group. ***P < 0.001, *P < 0.05; 
statistics: MC-TG versus saline. [MDSCs defined as CD11b+ 
MHCII−]
Fig. 3  MC-TG depletes circulating Mo-MDSCs and G-MDSCs and 
Mϕ in tumor-bearing mice. a–e E.G7-OVA tumor-bearing mice were 
injected 7 days p.i. with 10 mg/kg TG i.d. in the four footpads. a 
E.G7-OVA tumor volumes. Proportions over time (as percentage of 
CD45+ cells, left) and numbers on day 14 (per 100 μl blood, right) of 
circulating (b) Mo-MDSCs and (c) G-MDSCs. d Number of CD45+ 
leukocytes per 100 μl blood over time. e Proportions of Mϕ, B cells, 
and T cells (as percentage of CD45+ cells) in blood over time. f–h 
B16-F10 tumor-bearing mice were injected 5 days p.i. with 10 mg/
kg TG i.d. in all four footpads. f B16-F10 tumor volumes. Propor-
tion of (g) Mo-MDSCs (left) and G-MDSCs (right), and of (h) Mϕ, 
B cells, and T cells in the blood over time as percentage of CD45+ 
cells. Experiments repeated, 4–5 mice per group. ***P < 0.001, 
**P < 0.01, *P < 0.05, n.s. not significant. [MDSCs defined as 
CD11b+ MHCII−]
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MC-TG. Therefore, we hypothesized that nanosized formu-
lations become differentially effective only in vivo where 
biodistribution and transport, particularly in lymphatic 
drainage and LN targeting [53], are improved over the dif-
fuse and broader distribution of the free drug [54].
For in vivo studies, we chose the E.G7-OVA thymoma 
model for its strong MDSC recruitment and accumula-
tion [55]. MC-TG specifically depleted Mo-MDSCs in 
the spleen, G-MDSCs in LNs, and Mo-MDSCs in the 
tumor (Fig. 2). MC-TG depleted each MDSC subset in 
the relevant organ, making these findings very promising. 
Moreover, MC-TG targeted G-MDSCs in LNs, suggest-
ing that MC-TG efficiently drained through lymphatics, 
consistent with our previous biodistribution study on simi-
lar NPs [47]. While MC-TG did not deplete G-MDSCs in 
vitro, we hypothesize that the time difference between in 
vitro and in vivo experiments (3 vs 5–7 days) may explain 
the discrepancy between in vitro and in vivo observations. 
We previously showed that nanoparticulate carriers could 
associate externally with B and T cells without being inter-
nalized [47], which may explain why B cells associated 
with MC-TG in tumors without being depleted (Fig. 2e); 
further work is, however, needed to determine why B cells 
associated with MC-TG in tumors but not in spleens or 
LNs. High doses (100–200 μg) of CpG have been reported 
to deplete tumor Mo-MDSCs after intratumoral injection 
and to deplete splenic Gr1hi MDSCs after subcutaneous 
injection [36, 37]; however, this method required direct 
intratumoral injection to target tumor-infiltrating MDSCs, 
while we were able to target and deplete the same cells 
with indirect, passive i.d. delivery of MC-TG.
We next found that depletion of MDSCs in the blood 
peaked 7 days post-injection (Fig. 3) and that MC-TG 











































































































Fig. 5  MDSC depletion is dose dependent. a Injection timeline of 
E.G7-OVA tumor-bearing mice injected 7 days p.i. with a solution 
of 2, 5, or 10 mg/kg MC-TG i.d. in the four footpads. Proportion of 
(b) Mo-MDSCs and of (c) G-MDSCs in the blood, spleen, tumor, and 
LNs on day 14 as percentage of CD45+ cells. Three mice per group, 
***P < 0.001, **P < 0.01, *P < 0.05, statistics: MC-TG versus 
saline. [MDSCs defined as CD11b+ MHCII−]
Fig. 6  Depleting MDSCs with MC-TG enhances the efficacy of 
adoptive T cell therapy. a Injection timeline, b tumor volumes, and 
c survival of B16.OVA tumor-bearing mice injected with 10 mg/kg 
MC-TG i.d. in all four footpads 4 days p.i. and with 106 activated 
OT-I T cells adoptively transferred i.v. 6 days p.i. d Proportion of Mo-
MDSCs, G-MDSCs, Mϕ, DCs, B cells, and T cells in the blood (as 
percentage of CD45+); statistics vs all other groups. e Proportions 
of endogenous and transferred OT-I T cells on days 10 and 19 p.i. 
(as percentage of CD45+). f Phenotype of upper endogenous CD8+ 
and lower transferred OT-I CD8+ T cells 19 days p.i. in the blood: 
naive (CD44− CD62L+), central memory (CD44+ CD62L+), and 
effector (memory) (CD44+ CD62L−) T cells. 4–6 mice per group, 
***P < 0.001, **P < 0.01, *P < 0.05, n.d. no data. [MDSCs defined 
as CD11b+ MHCII−]
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depleted, MDSCs repopulated the blood to finally surpass 
their control populations, suggesting a compensatory mech-
anism in hematopoiesis. We hypothesized that Mo-MDSCs 
were more readily depleted because they can further divide 
and proliferate, while G-MDSCs cannot [56]. These results 
were reproducible in the B16-F10 melanoma model, which 
also recruits significant MDSC numbers [55]. Similarly to 
what has been reported with RA [10], depleting MDSCs 
with MC-TG did not affect tumor growth (Figs. 3, 6), sug-
gesting that MDSC depletion on its own did not sufficiently 
impact ongoing anti-tumor immunity. It has been shown 
that depletion of MDSCs with other drugs leads to delayed 
tumor growth, suggesting that MDSC depletion with 
MC-TG acts differently on E.G7-OVA and B16-F10 tumor 
growth than with other drugs [10, 11, 34, 35, 37]. While 
we aimed to specifically deplete MDSCs, the observation 
that MΦ were also targeted is not surprising given the use 
of TG and other thiopurine drugs as chemotherapeutics for 
myeloid and myelogenous leukemias, where monocyte and 
granulocyte precursors are targeted [42, 44].
Finally, we combined MC-TG treatment with two dif-
ferent modalities of cancer immunotherapy and found 
that our MDSC-depleting strategy enhanced adoptive T 
cell therapy and led to an enhanced effector phenotype of 
transferred OT-I CD8+ T cells (Fig. 6). This suggests that 
MC-TG created a period of time that enabled transferred 
T cells to infiltrate the tumor and kill tumor cells without 
being immune suppressed by the tumor microenvironment. 
Although other groups have reported that targeting MDSCs 
in combination with a cancer vaccine can improve immune 
outcomes [10, 11, 57], we found no therapeutic benefit in 
combining MC-TG treatment with a potent anti-tumor vac-
cine that delivered antigen and adjuvant to LNs (supple-
mentary Fig. S4) [50]. The lack of response to a LN-tar-
geting vaccine may be related to the transient reduction in 
other myeloid cells, namely MΦ and DCs, which may thus 
inhibit adaptive immunity to vaccination; this indeed cor-
related with a decrease in circulating OVA-specific CD8+ 
T cells. In contrast, the efficacy of adoptively transferred 
effector T cells, which do not require antigen presentation 
and priming steps, was enhanced when combined with 
MC-TG-mediated MDSC depletion (Fig. 6).
In summary, these data suggest that MC-TG can be 
used to efficiently target and deplete Mo-MDSCs and 
G-MDSCs, as well as monocytic MΦ. We further show 
that MC-TG was more efficacious than equivalent doses of 
free TG in depleting MDSCs in vivo, with a peak response 
after 7 days. When used in combination with adoptive 
transfer of activated, anti-tumor effector CD8+ T cells, 
MC-TG, but not free TG, could significantly improve 
therapeutic outcome by depleting suppressive MDSCs, 
thus allowing the T cells to be more effective in the tumor 
microenvironment.
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